

PROJECT LIVIN' LABEL

LABELING UNFOLDED - KNOWLEDGE RELEASED

AACR American Association
for Cancer Research*


FDA U.S. FOOD & DRUG
ADMINISTRATION



Episode 9 – Neo-adjuvant Nivolumab: The Backstory

Project Livin' Label Speaker Biographies

Oladimeji Akinboro, MD, Medical Oncologist - FDA Reviewer



Oladimeji (Ladi) Akinboro, MD, obtained his medical degree from the University of Ilorin, Ilorin, Nigeria. He completed residency training in internal medicine at the Montefiore Health System in New York. He proceeded to complete Hematology/Oncology fellowship training at the Boston University School of Medicine/Boston Medical Center. He joined the FDA as a medical officer in July 2020 and contributes to its public health mission as a clinical reviewer on the thoracic/head and cancer team in the Division of Oncology 2. He also serves as the co-lead of the FDA Oncology Center of Excellence's Project Site Selector and as an FDA representative on working groups of the International Association for the Study of Lung Cancer (IASLC) as well as the Society for Immunotherapy of Cancer (SITC). He has also been actively involved in FDA's joint educational programs with AACR and the American Society of Clinical Oncology (ASCO).

Jeevan Puthiamadathil, MD - Medical Oncology Fellow at National Cancer Institute (NCI)



Jeevan Puthiamadathil, MD, received his medical degree from Georgetown University School of Medicine and completed his internal medicine residency at MedStar Georgetown University Hospital in Washington, D.C. He completed his sub-specialty fellowship in Medical Oncology at the National Cancer Institute at the National Institutes of Health in Bethesda, MD, where he was an associate investigator for mesothelioma clinical trials. He subsequently joined the FDA as a medical officer, contributing to its public health mission as a clinical reviewer on the Thoracic/Head and Neck Cancer team in the Division of Oncology 2.

Abderrahim Oukessou, MD, VP, Development Program Lead, Oncology - Bristol-Myers Squibb



Abderrahim Oukessou, MD received his medical degree from the Medical University of Casablanca, Morocco and completed his residency hematology/oncology at the Assistance Publique des Hôpitaux in Paris, France. He serves as the Vice President, Development Program Lead, Lung/Head and Neck Cancer and cross-functional leadership of the Nivolumab development team. Prior to his current role, Abderrahim served as Executive Director and Clinical Team Leader of the Lung/Head and Neck program, providing oversight to the design of clinical development plans and leading global regulatory filings for a number of indications in the thoracic malignancies.

Patrick Forde, MD, Johns Hopkins University - IClinical Investigator



Patrick Forde, MD, is the Director of the Thoracic Cancer Clinical Research Program and Associate Professor of Oncology at Johns Hopkins Medicine. He is currently an associate member of the Bloomberg~Kimmel Institute for Cancer Immunotherapy and has acted as a lead developer of a clinical-translational research program focused on the immuno-oncology of upper aerodigestive malignancies. Dr. Forde is extremely active in research, often running multiple clinical trials at one time. His research focuses on the role of neoadjuvant anti-PD-1 therapy and other similar immunotherapies in earlier stage lung cancer and mesothelioma. Dr. Forde has also been involved in leading several international clinical trials of new immunotherapy approaches for lung cancer and mesothelioma that are currently active in Europe, Asia and North America, while also serving as the principal investigator for the thoracic cancer immunobiology biospecimen repository at Johns Hopkins Medicine. His work has been published in numerous publications, as well as receiving awards for his achievements in cancer research.

Dawn Vasco - Clinical Patient



Dawn Vasco, works as Alcohol Administrator at the Warner Graham company in Cockeysville, MD, where they repackage Ethanol for hospitals, pharmacies, universities, and NIH. She's been there for 32 years. Dawn has 4 children and 9 grandchildren.

Kevin Chen, PharmD, UNC Medical Center -Pharmacist



Kevin Chen is a clinical pharmacist practitioner at University of North Carolina (UNC) Medical Center specializing in the care of patients with thoracic malignancies and sarcoma. He completed his graduate and pharmacy education at the University of Kentucky College of Pharmacy, and subsequently went on to complete his oncology pharmacy residency at UNC Medical Center in 2020. His clinical interests center around precision medicine, dose-optimization of targeted therapies, and pharmacoeconomics. Kevin also holds an adjunct faculty position at the UNC Eshelman School of Pharmacy, where he hopes to expand our knowledge of evidence-based assessments for experiential education.